Intensity Therapeutics, Inc. (INTS) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Intensity Therapeutics, Inc. (INTS) Earnings Overview
As of June 30, 2026, Intensity Therapeutics, Inc. (INTS) reported trailing twelve-month net income of -$11M, reflecting +70.7% year-over-year growth. The company earned $-0.42 per diluted share over the past four quarters.
Looking at the long-term picture, INTS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2019.
Intensity Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), CLDX (-$284M net income, -17253.3% margin), NKTR (-$158M net income, -297.1% margin), INTS has comparable earnings metrics. Compare INTS vs IMVT →
INTS Earnings vs Peers
Earnings metrics vs comparable public companies
INTS Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | +28.7% | -$12M | $-8.56 | - | - |
| 2024 | -$16M | -54.4% | -$17M | $-29.25 | - | - |
| 2023 | -$11M | -39.0% | -$8M | $-34.50 | - | - |
| 2022 | -$8M | +4.0% | -$8M | $-55.50 | - | - |
| 2021 | -$8M | -32.6% | -$8M | $-58.00 | - | - |
| 2020 | -$6M | -13.9% | -$6M | $-44.25 | - | - |
| 2019 | -$5M | - | -$6M | $-39.50 | - | - |
Download Data
Export INTS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INTS — Frequently Asked Questions
Quick answers to the most common questions about buying INTS stock.
What is INTS earnings per share (EPS)?
INTS trailing twelve-month (TTM) diluted EPS is $-0.42, reflecting +70.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Intensity Therapeutics, Inc.'s net income?
Intensity Therapeutics, Inc. (INTS) trailing twelve-month net income is $-11M as of 2025. Earnings grew +70.7% year-over-year.
Is INTS profitable?
INTS is not currently profitable on a TTM basis, reporting a net loss of $-11M. Net margin is N/A. Investors should monitor for a return to profitability.
What is INTS's earnings growth rate?
INTS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are INTS's profit margins?
Intensity Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -156.9%.
Is INTS growing earnings?
Yes, INTS earnings are accelerating — EPS growth of +70.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-11M. Earnings momentum is strengthening.
What was INTS's best earnings year?
Intensity Therapeutics, Inc.'s highest annual net income on record is $-5M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were INTS's earnings last quarter?
INTS's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.96. For a full breakdown of all quarters, see the quarterly earnings table on this page.